BriaCell Therapeutics Closes $8.5 Million Offering-March 2024-www.financetom.com

BriaCell Therapeutics Closes $8.5 Million Offering

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BriaCell Therapeutics Closes $8.5 Million Offering

Sep 13, 2024 1:35 PM

04:36 PM EDT, 09/12/2024 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Thursday it closed an offering of 12.33-million shares, raising approximately $8.5 million.

Each common share was sold at an offering price of $0.69 per share.

The biotech company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes, and the advancement of business objectives.

BriaCell shares closed down $0.03 to $0.84 on the Toronto Stock Exchange.

Previous page： CGI Acquires Celero's Credit Union Business in Canada Next page： AbbVie Flags Hit to Q2 Adjusted Earnings from R&D Expenses, Revises 2024 Outlook

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

CGI Acquires Celero's Credit Union Business in Canada

Jul 5, 2024

03:47 AM EDT, 07/05/2024 (MT Newswires) -- CGI (GIB) said Thursday it has acquired Celero's business serving credit unions in Canada. The transaction includes relationships with more than 90 credit unions that span managed services, core banking, digital banking and related information technology services, the company said. Financial terms of the deal were not disclosed. Price: 102.11, Change: -0.08, Percent...

AbbVie Flags Hit to Q2 Adjusted Earnings from R&D Expenses, Revises 2024 Outlook

Jul 5, 2024

03:57 AM EDT, 07/05/2024 (MT Newswires) -- AbbVie ( ABBV ) expects its Q2 adjusted earnings to take a $0.52 per-share hit from acquired in-process research and development and milestones expense of $937 million on a pre-tax basis, according to a Wednesday regulatory filing. The company expects Q2 adjusted EPS of $2.53 to $2.57, including the impact, the filing showed....

Canada's GoviEx Uranium's stripped of Niger mining rights

Jul 5, 2024

JOHANNESBURG, July 5 (Reuters) - Canadian miner GoviEx Uranium ( GVXXF ) said its has been stripped of its right to develop a uranium project in Niger, just weeks after the West African country revoked a mining permit held by French firm Orano SA. GoviEx has been informed by Niger's mines ministry that it no longer holds the rights over...

Calliditas Therapeutics' Partner Launches Japanese Trial for IgA Nephropathy Treatment

Jul 5, 2024

03:56 AM EDT, 07/05/2024 (MT Newswires) -- Calliditas Therapeutics ( CALT ) said Thursday its partner Viatris Pharmaceutical Japan has launched a phase 3 clinical trial in Japan of Nefecon as a potential treatment for Japanese patients with IgA nephropathy, a disease of the kidney and the immune system. Calliditas licenses Nefecon, which is called VR-205 in Japan, to Viatris...